SCHEMBL2175871

SCHEMBL2175871

CNC(=O)COC(=O)N1CCN(CCCc2cccc(-c3ccc(Cl)cc3)c2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 5/20 0.52
HRH1 P35367 4/20 0.51
HRH2 P25021 3/20 0.51
MCL1 Q07820 1/20 0.44
SIGMAR1 Q99720 3/20 0.43
HTR2A P28223 2/20 0.43
OPRM1 P35372 2/20 0.43
ADORA3 P0DMS8 1/20 0.43
HTR7 P34969 1/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
DRD4 P21917 2/20 0.42
HTR1A P08908 1/20 0.42
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
HTT P42858 1/20 0.41
DRD2 P14416 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2175549 0.93 MEN1 (0.48) FAAHHRH1HRH2SIGMAR1HTR2A
SCHEMBL2177149 0.92 SIGMAR1 (0.51) FAAHHRH1HRH2SIGMAR1HTR2A
SCHEMBL2178351 0.91 FAAH (0.52) FAAHHRH1HRH2SIGMAR1HTR2A
SCHEMBL2178407 0.90 FAAH (0.62) FAAHHRH1HRH2SIGMAR1HTR2A
SCHEMBL2176110 0.90 HRH2 (0.53) FAAHHRH1HRH2SIGMAR1HTR2A
SCHEMBL2178312 0.87 SIGMAR1 (0.54) FAAHHRH1HRH2SIGMAR1HTR2A
SCHEMBL2175558 0.86 FAAH (0.50) FAAHHRH1HRH2SIGMAR1HTR2A
SCHEMBL2178066 0.86 FAAH (0.48) FAAHHRH1HRH2SIGMAR1HTR2A
SCHEMBL2177424 0.85 SIGMAR1 (0.56) FAAHHRH1SIGMAR1HTR2AOPRM1
SCHEMBL2179130 0.84 FAAH (0.65) FAAHHRH1HRH2SIGMAR1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720848-B1 DERIVATIVES OF ALKYLPIPERAZINE- AND ALKYLHOMOPIPERAZINE- CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS SANOFI AVENTIS (FR) 2007-12-05 EP claimed
US-7973042-B2 Derivatives of alkylpiperazine- and alkylhomopiperazine-carboxylates, preparation method thereof and use of same as fatty acid amido hydrolase enzyme inhibitors SANOFI-AVENTIS (FR) 2011-07-05 US disclosed
US-20090143365-A1 DERIVATIVES OF ALKYLPIPERAZINE- AND ALKYLHOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS SANOFI-AVENTIS (FR) 2009-06-04 US disclosed
US-7482346-B2 Derivatives of alkylpiperazine and alkylhomopiperazine-carboxylates, preparation method thereof and use of same as fatty acid amido hydrolase enzyme inhibitors SANOFI-AVENTIS (FR) 2009-01-27 US disclosed
US-20070027141-A1 DERIVATIVES OF ALKYLPIPERAZINE AND ALKYLHOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS SANOFI-AVENTIS (FR) 2007-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143365-A1 DERIVATIVES OF ALKYLPIPERAZINE- AND ALKYLHOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS FAAH, FAAH2, CNR2 FAAH 1/4885HRH1 45/4885HRH2 28/4885
US-20070027141-A1 DERIVATIVES OF ALKYLPIPERAZINE AND ALKYLHOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS FAAH, FAAH2, CNR2 FAAH 1/4885HRH1 40/4885HRH2 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.